OBJECTIVE: To assess the effectiveness of oral vanadium supplementation for glycaemic control in type 2 diabetes by conducting a systematic review of the literature. DESIGN AND METHODS: Eligible studies were identified by searching 14 databases using standardized terms. Experts, study authors and manufacturers were also contacted. Hand-searching was not undertaken. Selection criteria for inclusion in the review were controlled human trials of vanadium vs. placebo in adults with type 2 diabetes of minimum 2 months duration, and a minimum of 10 subjects per arm. Data extraction, assessment of study quality and outcome analysis were undertaken by two independent reviewers. RESULTS: One hundred and fifty one studies were found but none met the inclusion criteria. We proceeded to summarize the state of existing evidence and plan for a future clinical trial by applying revised, less restrictive criteria to our search, for clinical trials of 30-150 mg daily oral vanadium supplementation in diabetic humans. Only five were identified. These demonstrated significant treatment-effects, but due to poor study quality, must be interpreted with caution. Treatment with vanadium often results in gastrointestinal side-effects. CONCLUSION: There is no rigorous evidence that oral vanadium supplementation improves glycaemic control in type 2 diabetes. The routine use of vanadium for this purpose cannot be recommended. A large-scale randomized controlled trial is needed to address this clinical question.
OBJECTIVE: To assess the effectiveness of oral vanadium supplementation for glycaemic control in type 2 diabetes by conducting a systematic review of the literature. DESIGN AND METHODS: Eligible studies were identified by searching 14 databases using standardized terms. Experts, study authors and manufacturers were also contacted. Hand-searching was not undertaken. Selection criteria for inclusion in the review were controlled human trials of vanadium vs. placebo in adults with type 2 diabetes of minimum 2 months duration, and a minimum of 10 subjects per arm. Data extraction, assessment of study quality and outcome analysis were undertaken by two independent reviewers. RESULTS: One hundred and fifty one studies were found but none met the inclusion criteria. We proceeded to summarize the state of existing evidence and plan for a future clinical trial by applying revised, less restrictive criteria to our search, for clinical trials of 30-150 mg daily oral vanadium supplementation in diabetichumans. Only five were identified. These demonstrated significant treatment-effects, but due to poor study quality, must be interpreted with caution. Treatment with vanadium often results in gastrointestinal side-effects. CONCLUSION: There is no rigorous evidence that oral vanadium supplementation improves glycaemic control in type 2 diabetes. The routine use of vanadium for this purpose cannot be recommended. A large-scale randomized controlled trial is needed to address this clinical question.
Authors: Mohammed Selman; Christopher Rousso; Anabel Bergeron; Hwan Hee Son; Ramya Krishnan; Nader A El-Sayes; Oliver Varette; Andrew Chen; Fabrice Le Boeuf; Fanny Tzelepis; John C Bell; Debbie C Crans; Jean-Simon Diallo Journal: Mol Ther Date: 2017-10-24 Impact factor: 11.454
Authors: Gabriel A Borges; Liana P Webber; Ana Elizia M Marques; Eliete Ns Guerra; Rogerio M Castilho; Cristiane H Squarize Journal: Regen Med Date: 2020-03-30 Impact factor: 3.806
Authors: Arce Domingo-Relloso; Maria Grau-Perez; Laisa Briongos-Figuero; Jose L Gomez-Ariza; Tamara Garcia-Barrera; Antonio Dueñas-Laita; Jennifer F Bobb; F Javier Chaves; Marianthi-Anna Kioumourtzoglou; Ana Navas-Acien; Josep Redon-Mas; Juan C Martin-Escudero; Maria Tellez-Plaza Journal: Int J Epidemiol Date: 2019-12-01 Impact factor: 7.196
Authors: Esra Mutlu; Tim Cristy; Steven W Graves; Michelle J Hooth; Suramya Waidyanatha Journal: Environ Sci Pollut Res Int Date: 2016-10-10 Impact factor: 4.223
Authors: Thomas Scior; José Antonio Guevara-García; F J Melendez; Hassan H Abdallah; Quoc-Tuan Do; Philippe Bernard Journal: Drug Des Devel Ther Date: 2010-09-24 Impact factor: 4.162